Switzerland’s Roche said first-quarter sales dropped 7% on falling demand for its COVID-19 therapies and tests, less steep than analysts had expected thanks to strong revenue growth from a new eye drug.
https://www.pharmalive.com/wp-content/uploads/2022/04/ReuterRoche4-25-2022.webp6961200Reuters Healthhttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngReuters Health2023-04-26 08:26:212023-04-26 12:21:06Roche Q1 sales decline tempered by swift uptake of new eye drug
